Results 31 to 40 of about 71,664 (187)

De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer. [PDF]

Int J Cancer
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Ma Y, Chen D, Huang S.
europepmc   +2 more sources

SEC profiles showing the formation of HER2-trastuzumab-pertuzumab ternary complex.

, 2019
A. HER2 is first complexed with trastuzumab Fab and the binary complex elutes earlier than HER2 alone. The purified complex is further complexed with pertuzumab Fab and the ternary complex elutes earlier than the binary complex.
Yue Hao (1261215), Xin Huang (11077), Yonghong Bai (602344), Helen J. McBride (2306899), Xinchao Yu (6655553)   +4 more
core   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer [PDF]

Background While trastuzumab has been shown to improve disease-free and overall survival in patients with HER2-positive breast cancer, it may also cause trastuzumab-induced cardiotoxicity (TIC).
Vaynrub, Anna, Raikhelkar, Jayant, Mishalani, Leila, Crew, Katherine D.   +3 more
core   +1 more source

Tissue‐Agnostic Cellular Morphometric Biomarkers for Risk‐Adapted Management Across Gastrointestinal Precancerous Lesions and Cancers

Advanced Science, EarlyView.
An interpretable, unsupervised artificial intelligence framework identifies a 13‐cellular morphometric biomarker (CMB) signature from routine H&E whole‐slide images. Validated across 2,602 patients, the fixed signature generalizes across colorectal, gastric, and esophageal tissues without retraining, stratifies prognosis and precancerous lesion risk ...
Pin Wang, Chengfei Jiang, April W. Mao, Qi Sun, Yijun Lu, Jingjing Wei, Jamie L. Inman, Susan E. Celniker, Antoine M. Snijders, David W. Threadgill, Allan Balmain, Bo Hang, Hang Chang, Lei Wang, Jian‐Hua Mao   +14 more
wiley   +1 more source

AI‐Assisted Tumor Boundary Delineation via Targeted Ultrasmall Iron Oxide Nanoprobe for High‐Contrast HER2‐Positive Tumor Imaging

Advanced Science, EarlyView.
A novel targeted and pH‐responsive MRI contrast agent was integrated with a 3D nnU‐Net deep learning framework to enable accurate delineation of tumor boundary morphology in HER2‐positive breast cancer imaging. ABSTRACT Breast cancer continues to be a leading cause of cancer‐related mortality in women globally, where precise diagnosis and clear tumor ...
Jiaying Zheng, Yi Zhu, Xinrui Li, Sunxian Dai, Xiangyuan Ma, Hongwei Lu, Zhongling Wang, Benqing Zhou   +7 more
wiley   +1 more source

Antitumor activity of a novel TLR9 agonist and cooperativity with targeted agents [PDF]

, 2008
Novel modified Toll-like receptor 9 (TLR9) agonists, termed immune modulatory oligonucleotides (IMOs), exhibit antitumor activity and are currently investigated in cancer patients. Intriguingly, their mechanisms of action on tumor growth and angiogenesis
Garofalo, Sonia
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

A Case of Asymptomatic Left Ventricular Dysfunction during the Treatment of Metastatic Breast Cancer with Trastuzumab [PDF]

, 2002
We report a case of 29-year-old Japanese female with a history of resection of primary carcinoma of the right breast. After a partial response by chemotherapy with pirarubicin and docetaxel for lung metastasis, the patient developed multiple brain and ...
Maeda, Shigeto, Minami, Takako, Seto, Shinji, Ashizawa, Naoto, Yano, Katsusuke, Kaneko, Masayuki, Baba, Ken, Sugiyama, Nozomu   +7 more
core  

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source